Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kummer Laura Y L, Fernández Blanco Laura, Kreher Christine, Bos Amélie, Kuijper Lisan H, Verstegen Niels J M, van de Sandt Carolien E, Konijn Veronique A L, Duurland Mariël C, Menage Charlotte, Jorritsma Tineke, Steenhuis Maurice, Hagen Ruth R, van den Dijssel Jet, de Jongh Rivka, Ashhurst Tom, van Gils Marit J, Garcia-Vallejo Juan J, Claireaux Mathieu, Stalman Eileen W, van Dam Koos P J, Wieske Luuk, Boekel Laura, Wolbink Gertjan, Tas Sander W, Rispens Theo, Kuijpers Taco W, Eftimov Filip, van Ham Sija Marieke, Ten Brinke Anja, T2B! Immunity Against SARS-CoV-2 Study Group
Аннотация
METHODS: In the current study, we investigated the impact of MTX treatment in patients with immune-mediated inflammatory disease on B and CD4 T cell SARS-CoV-2 vaccination responses. Eighteen patients with RA and two patients with psoriatic arthritis on MTX monotherapy were included, as well as 10 patients with RA without immunosuppressive treatment, and 29 healthy controls. CD4 T and B cell responses were analysed 7 days and 3-6 months after two SARS-CoV-2 messenger RNA vaccinations. High-dimensional flow cytometry analysis was used to analyse fresh whole blood, an activation-induced marker assay to measure antigen-specific CD4 T cells, and spike probes to study antigen-specific B cells.
RESULTS: Seven days following two SARS-CoV-2 vaccinations, total B and T cell counts were similar between MTX-treated patients and controls. In addition, spike-specific B cell frequencies were unaffected. Remarkably, the frequency of antigen-specific CD4 T cells was reduced in patients using MTX and correlated strongly with anti-RBD IgG antibodies. These results suggest that decreased CD4 T cell activity may result in slower vaccination antibody responses in MTX-treated patients.
CONCLUSION: Taken together, MTX treatment reduces vaccine-induced CD4 T cell activation, which correlates with lower antibody responses.
TRIAL REGISTRATION NUMBER: NL8900.